Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma

This is an open-label, multi-center, multiple dose, Phase 1 study to evaluate the safety, tolerability, maximum tolerated dose (MTD) or maximum administered dose (MAD), pharmacokinetic (PK), pharmacodynamic, and recommended Phase 2 dose (RP2D) of TJ011133, an anti-CD47 antibody, in participants with advanced relapsed or refractory solid tumors and lymphoma. The study will be conducted in 2 parts. Part 1 comprises a single agent dose escalation (Part 1A) and 2 separate combination therapy dose escalations (Part 1B with pembrolizumab and Part 1C with rituximab) and Part 2 includes a dose expansion study.

Inclusion criteria

• Part 1: Participants with advanced relapsed/refractory solid tumors and lymphoma.
• Part 2 with Rituximab: Participants with diffuse large B-cell lymphoma (DLBCL) or Indolent B-cell Lymphoma, with at least one measurable lesion by Lugano and available fresh metastatic biopsy sample prior to study entry.
• Part 2 with Pembrolizumab: Participants with locally advanced non-small-cell lung carcinoma (NSCLC) with disease progression or immune-oncology treatment naive Epithelial ovarian cancer, fallopian tube, or primary peritoneal cancer, with at least one measurable lesion defined by Response Elevation Criteria in Solid Tumors (RECIST) 1.1, and available fresh metastatic biopsy prior to study entry.
• All Parts: Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 1 and adequate bone marrow, renal, and liver functions.

Exclusion criteria

• Participants with known symptomatic central nervous system tumors or known central nervous system metastases or leptomeningeal disease requiring steroids. Participants who document stable and central nervous system metastases and are off steroids for more than 4 weeks may be enrolled in the study.
• Participants with Burkitt's lymphoma, lymphoblastic lymphoma, Richter's transformation, primary effusion lymphoma or chronic lymphocytic leukemia/small lymphocytic lymphoma.
• Participants with mantle cell lymphoma.
• Impaired cardiac function or clinically significant cardiac diseases.
• Prior treatment with CD47 or SIRPα inhibitors.
• Prior autologous stem cell transplant <=3 months prior to starting study.
• Prior allogeneic stem cell transplant with either standard or reduced intensity conditioning.
• Prior chimeric antigen receptor or chimeric antigen receptor T-cell therapy.
• History of autoimmune anemia or autoimmune thrombocytopenia.
• Positive Direct Antiglobulin Test.
• Active graft versus host disease (GVHD) or ongoing immunosuppression for GVHD.